Abstract: The present disclosure teaches systems and methods for robotic welding of studs onto the surface of I-beams. The systems and methods use machine vision to identify and locate welding sites on a surface of a beam or girder, moves and aligns studs to the welding sites, and welds studs to the surface at these sites.

Abstract: A shear stud feeder for a stud welding gun may include a support frame having a first slide rail and a second slide rail longitudinally spaced apart from the first slide rail to form a slot therebetween. The shear stud feeder may also include a magazine removably engaged with the support frame. The magazine may be adapted to support a plurality of shear studs by the head of each shear stud in a manner in which the body of each shear stud hangs below a bottom of the magazine and wherein the magazine is adapted to dispense the plurality of shear studs to the slot. The shear stud feeder may include a feed mechanism disposed adjacent to either the first slide rail or the second slide rail and a gate assembly adjacent to a front end of each of the first slide rail and the second slide rail.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: A control device for a first lighting load on a vehicle or trailer features an input connected to a lighting circuit through which a different second lighting load is operated, thus placing the controller in parallel relation with the lighting circuit, and a power output connected to the first lighting load on the vehicle or trailer. The controller is configured to detect from the input, a signal change sequence in the lighting circuit that comprises an initial high-to-low signal downstep, and a subsequent low-to-high signal upstep completed within a limited time window triggered by the initial high-to-low signal downstep. In response to detection of this signal change sequence, the controller energizes the first lighting load. If the second lighting load is the vehicle headlights, for example, a user can turn on the first lighting load by momentarily flipping the headlight switch off, and then quickly back on again.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Abstract: The invention provides compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.

Abstract: A method of assembling a combustion system for a gas turbine engine includes providing a combustion chamber frame, an inner casing structure, and an outer casing structure. The method also includes mounting the combustion chamber frame between the inner casing structure and the outer casing structure such that the combustion chamber frame is coupled to the inner casing structure and the outer casing structure.

Abstract: A method of manufacturing a component suitable for use in a gas turbine engine, comprising the steps of forming the component from a substrate having a first surface and a second surface, forming at least one aperture through the substrate from the first surface to the second surface having a first open area, applying a first coating to at least one of the first surface and the second surface adjacent to the at least one aperture, the aperture remaining at least partially unobstructed by the first coating, applying a second coating to the first coating adjacent to the at least one aperture, the aperture remaining at least partially unobstructed by the second coating, and removing the second coating from the aperture, leaving most or all of the first coating to define a second open area which is smaller than the first open area.

Abstract: A method is provided for controllably delivering an additive fluid into a host fluid in a target system at a desired volumetric flow rate. The method comprises: providing a binary supply injector connected in an additive fluid delivery system between a pressurized supply of the additive fluid and the target system. The binary supply injector is controllable between an ON state which permits flow of the additive fluid therethrough and an OFF state which prevents flow of the additive fluid therethrough. The method involves iteratively repeating: estimating a volumetric flow rate of the additive fluid between the pressurized supply and the target system; and if the estimated volumetric flow rate of the additive fluid is greater than the desired volumetric flow rate, controlling the supply injector to its OFF state; or if the estimated volumetric flow rate of the additive fluid is less than the desired volumetric flow rate, controlling the supply injector to its ON state.